These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23029104)

  • 21. Insights into Hyperparathyroidism-Jaw Tumour Syndrome: From Endocrine Acumen to the Spectrum of
    Gheorghe AM; Sima OC; Florescu AF; Ciuche A; Nistor C; Sandru F; Carsote M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitivity of HRPT2 mutation screening to detect parathyroid carcinoma and atypical parathyroid adenoma of Thai patients.
    Niramitmahapanya S; Sunthornthepvarakul T; Deerochanawong C; Sarinnapakorn V; Athipan P; Harnsomboonvana P; Kongsaengdao S
    J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S17-22. PubMed ID: 21717873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors.
    Wang O; Wang CY; Shi J; Nie M; Xia WB; Li M; Jiang Y; Guan H; Meng XW; Xing XP
    Chin Med J (Engl); 2012 Aug; 125(16):2895-901. PubMed ID: 22932087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotype of CDC73 germline mutation determines risk of parathyroid cancer.
    Li Y; Zhang J; Adikaram PR; Welch J; Guan B; Weinstein LS; Chen H; Simonds WF
    Endocr Relat Cancer; 2020 Sep; 27(9):483-494. PubMed ID: 32590342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism.
    Bricaire L; Odou MF; Cardot-Bauters C; Delemer B; North MO; Salenave S; Vezzosi D; Kuhn JM; Murat A; Caron P; Sadoul JL; Silve C; Chanson P; Barlier A; Clauser E; Porchet N; Groussin L;
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E403-8. PubMed ID: 23293331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on parathyroid carcinoma.
    Cetani F; Pardi E; Marcocci C
    J Endocrinol Invest; 2016 Jun; 39(6):595-606. PubMed ID: 27001435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer.
    Cetani F; Banti C; Pardi E; Borsari S; Viacava P; Miccoli P; Torregrossa L; Basolo F; Pelizzo MR; Rugge M; Pennelli G; Gasparri G; Papotti M; Volante M; Vignali E; Saponaro F; Marcocci C
    Endocr Connect; 2013; 2(4):186-95. PubMed ID: 24145611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
    Cetani F; Pardi E; Ambrogini E; Banti C; Viacava P; Borsari S; Bilezikian JP; Pinchera A; Marcocci C
    J Endocrinol Invest; 2008 Oct; 31(10):900-4. PubMed ID: 19092296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors.
    Newey PJ; Bowl MR; Cranston T; Thakker RV
    Hum Mutat; 2010 Mar; 31(3):295-307. PubMed ID: 20052758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours.
    Bradley KJ; Cavaco BM; Bowl MR; Harding B; Cranston T; Fratter C; Besser GM; Conceição Pereira M; Davie MW; Dudley N; Leite V; Sadler GP; Seller A; Thakker RV
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):299-306. PubMed ID: 16487440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial isolated primary hyperparathyroidism/hyperparathyroidism-jaw tumour syndrome caused by germline gross deletion or point mutations of CDC73 gene in Chinese.
    Kong J; Wang O; Nie M; Shi J; Hu Y; Jiang Y; Li M; Xia W; Meng X; Xing X
    Clin Endocrinol (Oxf); 2014 Aug; 81(2):222-30. PubMed ID: 24716902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.
    Juhlin CC; Villablanca A; Sandelin K; Haglund F; Nordenström J; Forsberg L; Bränström R; Obara T; Arnold A; Larsson C; Höög A
    Endocr Relat Cancer; 2007 Jun; 14(2):501-12. PubMed ID: 17639063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
    Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
    Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease.
    Tominaga Y; Tsuzuki T; Matsuoka S; Uno N; Sato T; Shimabukuro S; Goto N; Nagasaka T; Uchida K
    World J Surg; 2008 May; 32(5):815-21. PubMed ID: 18338208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HRPT2 gene analysis and the diagnosis of parathyroid carcinoma.
    Cetani F; Pardi E; Banti C; Borsari S; Ambrogini E; Vignali E; Cianferotti L; Viccica G; Pinchera A; Marcocci C
    Expert Rev Endocrinol Metab; 2008 May; 3(3):377-389. PubMed ID: 30754207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of malignant parathyroid tumours in two European cohorts of patients with sporadic primary hyperparathyroidism.
    Ozolins A; Narbuts Z; Vanags A; Simtniece Z; Visnevska Z; Akca A; Wirowski D; Gardovskis J; Strumfa I; Goretzki PE
    Langenbecks Arch Surg; 2016 Nov; 401(7):943-951. PubMed ID: 26658808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor suppressor gene mutation in a patient with a history of hyperparathyroidism-jaw tumor syndrome and healed generalized osteitis fibrosa cystica: a case report and genetic pathophysiology review.
    Parfitt J; Harris M; Wright JM; Kalamchi S
    J Oral Maxillofac Surg; 2015 Jan; 73(1):194.e1-9. PubMed ID: 25511968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical and morphological characteristics of parathyroid carcinoma].
    Voronkova IA; Mokrysheva NG; Kazantseva IA; Gurevich LE
    Arkh Patol; 2018; 80(4):65-72. PubMed ID: 30059074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The EIF4EBP3 translational repressor is a marker of CDC73 tumor suppressor haploinsufficiency in a parathyroid cancer syndrome.
    Zhang JH; Seigneur EM; Pandey M; Loshakov A; Dagur PK; Connelly PS; Koo L; Panicker LM; Simonds WF
    Cell Death Dis; 2012 Feb; 3(2):266. PubMed ID: 22297294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A germline mutation of HRPT2/CDC73 (70 G>T) in an adolescent female with parathyroid carcinoma: first case report and a review of the literature.
    Serrano-Gonzalez M; Shay S; Austin J; Maceri DR; Pitukcheewanont P
    J Pediatr Endocrinol Metab; 2016 Sep; 29(9):1005-12. PubMed ID: 27544721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.